-
Notable Put Options Activity in Seattle Genetics
Monday, August 29, 2011 - 10:57am | 96Shares of Seattle Genetics (NASDAQ: SGEN) are higher on the session by 1.20%, currently trading at $16.86. The stock has been moving largely higher over the past three weeks and is currently trading above the 50-day moving average. Options traders are focusing on puts today. A short while ago the...
-
Morning Gainers; Dresser-Rand Group up 11%
Monday, August 29, 2011 - 10:14am | 140Dresser-Rand Group Inc. (NYSE: DRC) +11.65% - hearing that the company was upgraded to Add by a mid-tier analyst firm. LyondellBasell Industries (Public, NYSE: LYB) +6.00% on heavy volume. DryShips Inc. (Public, NASDAQ: DRYS) +6.23% after announcing an exchange offer of shares of Ocean Rig....
-
ACADIA Pharmaceuticals Spikes Higher
Monday, August 29, 2011 - 10:03am | 113Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) are spiking higher this morning; currently, shares are higher by 8.73%, trading at $1.37. The stock has been consolidating above the $1.20 level since forming a high volume bottom on August 8th. Shares are now testing the 20-day moving average. If...
-
Cardium Provides Update on Exchange Listing and Related Business Matters
Monday, August 29, 2011 - 9:06am | 243Cardium Therapeutics (NYSE: CXM) reported that it had submitted a modified compliance plan designed to reestablish compliance with its exchange listing requirements in view of ongoing plans related to the acquisition of a revenue-generating nutraceutical business designed to expand the Company's...
-
Icagen Reaffirms Recommendation to Shareholders to Tender Shares
Monday, August 29, 2011 - 8:53am | 56Icagen (NASDAQ: ICGN) announced today that it has sent the following letter to stockholders affirming the Board's recommendation after receiving a letter from Pfizer (NYSE: PFE) on Friday, August 26, 2011 stating that Pfizer's best and final offer price is $6.00 per share:
-
Wedbush Comments On Dendreon's Approval Of Atlanta Facility By FDA
Monday, August 29, 2011 - 7:29am | 129Wedbush Securities has published a research report on Dendreon (NASDAQ: DNDN) after discovering that the FDA approved the company's Atlanta Provenge facility. In the report, Wedbush writes, "[W]e agree with management that urologists' practices tend not to have the working capital required to buy...
-
QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System
Monday, August 29, 2011 - 6:55am | 142QLT Inc. (Nasdaq: QLTI) today announced results of its Phase II clinical study on the efficacy and safety of the Latanoprost Punctal Plug Delivery System in subjects with ocular hypertension and open-angle glaucoma. The Phase II trial featured simultaneous placement of punctal plugs in both the...
-
FDA Approves Dendreon's Atlanta Cancer Immunotherapy Manufacturing Facility
Friday, August 26, 2011 - 3:28pm | 99Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration approved its Atlanta cancer immunotherapy manufacturing facility, the third location at which the Company will produce PROVENGE® to help meet the needs of patients across the U.S. with asymptomatic or...
-
UPDATE: Citi Downgrades Regeneron To Hold
Friday, August 26, 2011 - 7:59am | 69According to Citi, Regeneron Pharmaceuticals (NASDAQ: REGN) is downgraded to Hold. Citi said that due to an error in the working capital section of our DCF analysis, it is adjusting its model. “As our new $60 target price that is based on sum of the parts (including DCF) runs into valuation...
-
Benzinga's Top Downgrades
Friday, August 26, 2011 - 7:49am | 126Morgan Stanley downgraded Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT) from “overweight” to “equal-weight.” HOT's shares closed at $40.67 yesterday. HOT's trailing-twelve-month ROA is 3.93%. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by Citigroup from "buy" to "hold."...
-
Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine
Friday, August 26, 2011 - 6:53am | 182Emergent BioSolutions Inc. (NYSE: EBS) announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology...
-
Citigroup Downgrades Regeneron Pharmaceuticals To Hold, Lowers PT To $60
Friday, August 26, 2011 - 6:15am | 27Citigroup has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from Buy to Hold and has lowered the price target from $68 to $60.
-
Gilman and Pastor, LLP Announces a Securities Fraud Class Action Lawsuit
Thursday, August 25, 2011 - 4:34pm | 55Gilman and Pastor, LLP announces that a lawsuit seeking class action status has been filed in the United States District Court for the Western District of Washington at Seattle on behalf of the purchasers of Dendreon Corporation (NASDAQ: DNDN) who purchased shares between January 7, 2011 and August...
-
UPDATE: Ladenburg Thalmann Lowers PT on United Therapeutics
Thursday, August 25, 2011 - 9:27am | 124Ladenburg Thalmann has published a research report on United Therapeutics (NASDAQ: UTHR) lowering the price target. In the report, Ladenburg Thalmann wrote, "FREEDOM-C2 fails to achieve statistical significance. The primary endpoint was the median hange in 6MWD at week 16 from baseline which...
-
Ladenburg Thalmann Lowers PT On United Therapeutics To $61
Thursday, August 25, 2011 - 8:38am | 27Ladenburg Thalmann has lowered the price target on United Therapeutics (NASDAQ: UTHR) from $85 to $61 and maintains its Buy rating.